ABOS Acumen Pharmaceuticals, Inc.
USHealthcareAs of 2026-08-24
Why ABOS matters now
Acumen Pharmaceuticals, Inc. (ABOS) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.08 with -2.69% on the session and $222.1M in market capitalization; recent performance reads 1-month +4.15% and YTD +7.11%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-20.7M, and EPS of $-0.33. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -77.1%.
The latest indexable market news headline is "Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.00; recent insider activity includes Porter Derrell filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.63
P/S
0.00
EV/EBITDA
-1.07
DCF Value
$0.38
FCF Yield
-77.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-123.1%
ROA
-84.8%
ROIC
-96.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-20.7M | $-0.33 |
| Q4 2025 | $0.00 | $-25.1M | $-0.42 |
| FY 2025 | $0.00 | $-121.3M | $-2.00 |
| Q3 2025 | $0.00 | $-26.5M | $-0.44 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.35
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.